Role of human Keap1 S53 and S293 residues in modulating the binding of Keap1 to Nrf2
Authors:
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31460226, 31760246)
- Natural Science Foundation of Hainan Province (317039)
This publication has 30 references indexed in Scilit:
- Nrf2, cellular redox regulation, and neurologic implicationsNeurology, 2017
- The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseasesBiophysical Reviews, 2016
- The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An UpdateMedicinal Research Reviews, 2016
- Discovery of direct inhibitors of Keap1–Nrf2 protein–protein interaction as potential therapeutic and preventive agentsActa Pharmaceutica Sinica B, 2015
- Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a ReviewCurrent Medicinal Chemistry, 2014
- The emerging role of the Nrf2–Keap1 signaling pathway in cancerGenes & Development, 2013
- The cytoprotective role of the Keap1–Nrf2 pathwayArchives of Toxicology, 2011
- NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancerTrends in Biochemical Sciences, 2009
- Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activationNature Genetics, 2003
- Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domainGenes & Development, 1999